Ovarian Cancer Study Reveals High Incidence of Blood Clots in Patients on PARP Inhibitors

Strategic Insights -

A recent study conducted by the Spanish Society of Medical Oncology (SEOM) has shed light on the risks associated with PARP inhibitors in ovarian cancer patients. The research aimed to determine the real-world incidence and predictive factors for venous and arterial thromboembolic events (VTE/AT) in patients treated with these inhibitors. The study analyzed data from 329 patients who initiated PARP treatment between January 2015 and December 2022, revealing a striking 4.9% incidence of VTE/AT.

Key Takeaways:

  • The study found a 4.9% incidence of VTE/AT among ovarian cancer patients treated with PARP inhibitors.
  • BRCA2 mutations were significantly more prevalent among patients who developed VTE/AT (56.3% vs. 19.2%).
  • The study concludes that these findings may be of interest when designing future clinical trials in the field of thromboprophylaxis.
  • The study suggests that ovarian cancer patients on PARP inhibitors should be closely monitored for signs of VTE/AT.
  • Manuel Sanchez Canovas and his team conducted the research, which was reported in Clinical and Translational Oncology in 2025.

Statistics:

  • 329 ovarian cancer patients were included in the study, with 16 (4.9%) developing VTE/AT.
  • The incidence of VTE/AT was significantly higher among patients with BRCA2 mutations (56.3% vs. 19.2%).
  • The study was conducted between January 2015 and December 2022.
  • The Spanish Society of Medical Oncology (SEOM) thrombosis and cancer group was responsible for the study.
  • 16 patients out of 329 (4.9%) developed VTE/AT.

Sources:

  • NewsRx. "New Ovarian Cancer Study Findings Have Been Reported from Manuel Sanchez Canovas et al [PARP inhibitors-associated thrombosis in patients with ovarian cancer: a study of the Spanish Society of Medical Oncology (SEOM) thrombosis and cancer group]". OBGYN & Reproduction Week. September 22, 2025; p 435.
  • PARP inhibitors-associated thrombosis in patients with ovarian cancer: a study of the Spanish Society of Medical Oncology (SEOM) thrombosis and cancer group. Clinical and Translational Oncology, 2025.